Norges Bank’s Kalaris Therapeutics KLRS Stock Holding History

Norges Bank’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,174	Closed	-$1.92M	–	2201
2020 Q4	$1.92M	Hold	2,174	–	–	﹤0.01%	1957
2020 Q3	$1.38M	Buy	+2,174	New	+$1.48M	﹤0.01%	2002

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Norges Bank's KLRS Position: Q1 2021 in Review

Norges Bank sold out of Kalaris Therapeutics (KLRS) in Q1 2021, closing a stake of 2,174 shares — an estimated $1.92M sold.

Norges Bank first reported a position in KLRS in Q3 2020 and held it in 2 quarters. The position peaked at $1.92M in Q4 2020. 75 funds tracked by Wall St. Rank hold KLRS as of Q1 2021.

Norges Bank reported no remaining Kalaris Therapeutics position as of Q1 2021 after selling out during the quarter.
Norges Bank sold 2,174 Kalaris Therapeutics shares in Q1 2021, an estimated $1.92M.
Norges Bank first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 2 quarters.
Norges Bank's Kalaris Therapeutics position peaked at $1.92M in Q4 2020.
75 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2021.

Based on Norges Bank's 13F filing for Q1 2021, filed 7 May 2021.